News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AbbVie (ABBV) Beats Estimates as Sales of Humira Continues Climb


7/26/2013 7:15:42 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AbbVie Inc. (ABBV), the drugmaker carved out of Abbott (ABT) Laboratories at the start of the year, reported profit that beat analyst estimates and raised its 2013 forecast after sales of top medicine Humira gained on price increases and new indications. Earnings, excluding one-time items, of 82 cents a share topped by 3 cents the average of 10 analysts’ estimates compiled by Bloomberg. Full-year profit is expected to be $3.07 to $3.13 a share, the Abbott Park, Illinois-based company said in a statement today. Its previous outlook was for profit of at least $3.03 a share.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Reuters


comments powered by Disqus
Bloomberg
Reuters
AbbVie
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES